IOL Chemicals And PharmaceuticalsNSE:IOLCP +2.06%68 EBITDA Margin % is 15.22% as of Mar. 2026, which is 22% above its 10-year median of 12.51. GuruFocus rates NSE:IOLCP with a GF Score™ of 68/100 and a GF Value™ of ₹93.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, IOL Chemicals And Pharmaceuticals ranks worse than 50.79% on this metric.
IOL Chemicals And Pharmaceuticals (NSE:IOLCP) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
IOL Chemicals And Pharmaceuticals EBITDA Margin % Related Terms
IOL Chemicals And Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IOL Chemicals And Pharmaceuticals EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, IOL Chemicals And Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IOL Chemicals And Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, IOL Chemicals And Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where IOL Chemicals And Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IOL Chemicals And Pharmaceuticals (NSE:IOLCP) has a EBITDA Margin % of 15.22% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IOL Chemicals And Pharmaceuticals and its competitors. This is 22% above median its historical median of 12.51. Over the past decade, IOL Chemicals And Pharmaceuticals' EBITDA Margin % has ranged from 10.81 to 31.41. According to the industry distribution chart, IOL Chemicals And Pharmaceuticals ranks #485 out of 955 companies in the Drug Manufacturers industry, placing it in the top 50.8%.
Is IOL Chemicals And Pharmaceuticals' EBITDA Margin % too high?
IOL Chemicals And Pharmaceuticals' current EBITDA Margin % of 15.22% is 22% above median its 10-year median of 12.51. Over the past 10 years, this metric has ranged from a low of 10.81 to a high of 31.41. The Drug Manufacturers industry median EBITDA Margin % is 12.39. IOL Chemicals And Pharmaceuticals' value of 15.22% is 22.8% above this industry median. Based on the distribution chart, IOL Chemicals And Pharmaceuticals ranks #485 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, IOL Chemicals And Pharmaceuticals has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IOL Chemicals And Pharmaceuticals' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, IOL Chemicals And Pharmaceuticals ranks #485 out of 955 companies for EBITDA Margin %. This places IOL Chemicals And Pharmaceuticals in the lower half of its industry. The industry median EBITDA Margin % is 12.39. IOL Chemicals And Pharmaceuticals' value of 15.22% is 22.8% above this benchmark. Historically, IOL Chemicals And Pharmaceuticals' own EBITDA Margin % has ranged from 10.81 to 31.41 over the past decade. While the company's 10-year median is 12.51 vs. the industry median of 12.39, IOL Chemicals And Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IOL Chemicals And Pharmaceuticals's current EBITDA Margin % of 15.22% is 22.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IOL Chemicals And Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IOL Chemicals And Pharmaceuticals's current EBITDA Margin % is 15.22%, which is 22% above median its own 10-year median of 12.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IOL Chemicals And Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, IOL Chemicals And Pharmaceuticals (NSE:IOLCP) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹93.62, compared to a current price of ₹133.66 — trading 42.8% above its estimated fair value. The current EBITDA Margin % is 15.22%, which is 22% above median its 10-year median of 12.51 and 22.8% above the Drug Manufacturers industry median of 12.39. IOL Chemicals And Pharmaceuticals' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For IOL Chemicals And Pharmaceuticals (NSE:IOLCP), the current EBITDA Margin % is 15.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IOL Chemicals And Pharmaceuticals (NSE:IOLCP) Overvalued in 2026?
Based on GuruFocus' analysis, IOL Chemicals And Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹133.66 is trading 42.8% above its estimated GF Value™ of ₹93.62.
GuruFocus considers IOL Chemicals And Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:IOLCP:
EBITDA Margin %: 15.22% (22% above median its 10-year median of 12.51)
GF Value™: ₹93.62 vs. price of ₹133.66 (42.8% above fair value)
Industry Position: 22.8% above the Drug Manufacturers median (#485 of 955)
No single metric tells the full story. See the NSE:IOLCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IOL Chemicals And Pharmaceuticals Business Description
IOL Chemicals And Pharmaceuticals Ltd is an India-based pharmaceutical company. The primary activity of the group is the manufacturing and sale of drugs and organic chemicals. The business activity is functioned through the Chemicals and Pharmaceutical segments. The Chemicals segment produces and sells chemicals such as Ethyl Acetate, Acetic Anhydride, Acetyl Chloride, Mono Chloro Acetic Acid, and Iso Butyl benzene, whereas the Pharmaceutical segment produces and sells various active pharmaceutical ingredients such as Ibuprofen, Metformin, Fenofibrate, Lamotrigine, and others. It derives prime revenue from the Pharmaceutical segment. Geographically, the group's products are sold in both the Indian and international markets.
68GF Score
Get the complete analysis for NSE:IOLCP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:IOLCP has been successfully added to your 
